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Abstract
Goals—We describe the relationship between preoperative Magnetic Resonance Imaging (MRI) 
and the utilization of additional imaging, biopsy, and primary surgical treatment for subgroups of 
women with interval versus screen-detected breast cancer. We determined the proportion of 
women receiving additional breast imaging or biopsy and type of primary surgical treatment, 
stratified by use of preoperative MRI, separately for both groups.
Methods—Using Breast Cancer Surveillance Consortium (BCSC) data, we identified a cohort of 
women age 66 and older with an interval or screen-detected breast cancer diagnosis between 
2005–2010. Using logistic regression, we explored associations between primary surgical 
treatment type and preoperative MRI use for interval and screen-detected cancers.
Results—There were 204 women with an interval cancer and 1254 with a screen-detected 
cancer. The interval cancer group was more likely to receive preoperative MRI (21% vs. 13%). In 
both groups, women receiving MRI were more likely to receive additional imaging and/or biopsy. 
Receipt of MRI was not associated with increased odds of mastectomy (OR =0.99, 95% CI: 0.67–
1.50), while interval cancer diagnosis was associated with significantly higher odds of mastectomy 
(OR=1.64, 95% CI: 1.11–2.42).
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Conclusion—Older women with interval cancer were more likely than women with a screen-
detected cancer to have preoperative MRI, however, those with an interval cancer had 64% higher 
odds of mastectomy regardless of receipt of MRI. Given women with interval cancer are reported 
to have a worse prognosis, more research is needed to understand effectiveness of imaging 
modalities and treatment consequences within this group.
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Introduction
Preoperative MRI refers to the use of MRI as part of a clinical evaluation following a breast 
cancer diagnosis and before primary surgery. It is used to determine the extent of disease and 
to detect additional disease not detected at initial presentation in women with a newly 
diagnosed breast cancer (1). Preoperative MRI usage has increased from 10% in 2003 to 27–
40% in 2007 (1). Multiple clinical trials and a meta-analysis have shown that breast MRI 
detects otherwise occult cancer in an average of 16% of women in the ipsilateral breast (2) 
and 3–10% in the contralateral breast (3–6). Evidence shows that preoperative MRI detected 
contralateral breast cancers in 6% of women with an infiltrating lobular carcinoma, 3.4 % 
with invasive cancer, and 3% with ductal carcinoma in situ (DCIS) (6). Studies comparing 
the effectiveness of preoperative breast MRI to mammography and/or ultrasound for both 
work-up and outcomes have found that with the detection of additional disease comes 
additional work-up and possibly more extensive surgery (7–10). While recent studies have 
begun to investigate the surgical management and clinical outcomes associated with 
preoperative MRI, such as mastectomy rates, local recurrence and survival, the initial reports 
are conflicting (1), with several recent studies reporting no benefit (11–13) (1). This 
controversy around the benefits of preoperative MRI (14) (10) (15) (1) continues, and 
research and assessment among patient subgroups is emerging (16–18) (8).
One important subgroup not currently investigated in the preoperative MRI literature is 
women with an interval breast cancer diagnosis. Interval breast cancers are those diagnosed 
after a negative screening mammogram and before the next routine screening examination. 
Approximately 10%–20% of breast cancers are not routinely detected during a 
mammography screening (19, 20). Interval cancers have been shown to have a poorer 
prognosis than screen-detected cancers, with a higher proportion being invasive lobular, 
more advanced in stage, less differentiated, triple-negative, and having lower 5-year survival 
(21–23). Therefore, understanding the utilization of advanced imaging, additional biopsy, 
and primary surgical treatment for women with an interval versus screen-detected cancer is 
important to inform comparative effectiveness studies on the clinical utility of preoperative 
breast MRI.
The purpose of our study was to better understand and describe the relationship between 
preoperative MRI and utilization of additional imaging, biopsy, and surgical outcomes for 
subgroups of women with interval or screen-detected breast cancer. We hypothesized that in 
women with a diagnosis of interval breast cancer, preoperative MRI would be more strongly 
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associated with use of additional imaging, biopsy and mastectomy versus women with a 
screen-detected breast cancer. Therefore, we examined 1) the relationships between 
preoperative MRI use and receipt of additional imaging and/or biopsy for women with 
interval cancer versus screen-detected diagnoses and 2) the relationships between 
preoperative MRI use and primary surgical treatment (mastectomy or breast conserving 
surgery) for women with interval and screen-detected cancer diagnoses.
Materials and Methods
Data Sources
Data for this study was obtained from the Breast Cancer Surveillance Consortium (BCSC) 
Data Resource. More information regarding this resource is available at: http://
breastscreening.cancer.gov/. The study population included women from the Breast Cancer 
Surveillance Consortium (BCSC) whose registry records have been linked to Medicare 
claims. The BCSC is a national collaboration of breast cancer screening registries that has 
been funded by the National Cancer Institute since 1996 (24). Data were obtained from four 
BCSC registries -Carolina Mammography Registry, New Hampshire Mammography 
Network, San Francisco Mammography Registry, and Vermont Breast Cancer Surveillance 
System - that participated in linkage of BCSC records and Medicare Claims data. 
Information collected by the BCSC includes breast cancer radiology examination 
information (e.g. indication for examination, mammography interpretation using Breast 
Imaging Report and Data System - (BIRADS®) (25), recommended follow-up after 
imaging, and breast density) linked to information from state cancer registries (24).
We used beneficiary and billing data collected by the Centers for Medicare and Medicaid 
Services (CMS) for inpatient (MedPAR), hospital outpatient (Outpatient), and physician 
services (Carrier). Billing data provided information on procedures based on International 
Classification of Disease, Version 9 (ICD-9), Current Procedure Terminology (CPT), and 
Healthcare Common Procedure Coding System (HCPCS) codes. In addition, the Medicare 
enrollment file maintains data on demographic factors, vital status, enrollment and eligibility 
status for Medicare benefits. Data were pooled at a central Statistical Coordinating Center 
(SCC) at Group Health Research Institute (Seattle, WA). The SCC and all BCSC registries 
received Institutional Review Board approval for active or passive consenting processes or a 
waiver of consent to enroll participants, link data and conduct analysis. All procedures were 
Health Insurance Portability and Accountability Act (HIPAA) compliant and all registries 
and the SCC have received a Federal Certificate of Confidentiality and other protection for 
the identities of women, physicians, and facilities who are subjects of this research.
Study Population
Among women from the four BCSC registries linked to Medicare claims, the study cohort 
included those who were 66 years of age or older at the time of a BCSC-captured screening 
mammogram in 2005–2009 (N=212,953). Among these women, 2,741 had a breast cancer 
diagnosis within 365 days following a screening mammogram. To ensure complete capture 
of Medicare claims, we included women who were enrolled in Medicare parts A and B and 
were not enrolled in a Medicare HMO for one year prior to and six months post breast 
Goodrich et al. Page 3













cancer diagnosis (N=1,552). Finally, we restricted the cohort to women who had primary 
breast surgery within 6 months of diagnosis (N=1,458).
Measures and Definitions
The primary predictor, interval versus screen-detected cancer, was defined based on the 
assessment and recommendations from the BCSC screening mammogram. An interval 
cancer was defined as a breast cancer diagnosed within 365 days following a negative 
screening mammogram (BIRADS 1, 2, or 3 without recommendation for immediate 
evaluation). A screen-detected cancer was defined as a breast cancer diagnosis occurring 
within 365 days following a positive screening mammogram (BIRADS 0, 4, 5, or 3 with 
recommendation for immediate evaluation) (26). Women with any MRI in Medicare claims, 
based on CPT/HCPCS or ICD-9 codes (see Appendix A), found from the breast cancer 
diagnosis date up to and including the primary surgical treatment date were defined as 
having a preoperative MRI.
Primary surgical treatment was defined as the first breast cancer surgery within six months 
of breast cancer diagnosis and was classified as mastectomy or breast conserving surgery 
based on cancer registry data captured by the BCSC. Medicare claims were used to define 
any additional breast imaging (mammography or ultrasound) or biopsy (see Appendix A) 
within a six month window between the breast cancer diagnosis and primary surgical 
treatment.
Patient characteristics including age at diagnosis, race/ethnicity, education, parity, age at 
menarche, family history of breast cancer, personal history of breast biopsy, radiologic-
reported breast imaging-reporting (BIRADS) breast density, and five-year breast cancer risk 
(a cutoff of 1.67 for delineating between lower and higher five-year breast cancer risk) (27) 
were identified using BCSC data. Education, parity, family history of breast cancer, personal 
history of breast biopsy, breast density, and five-year breast cancer risk, were captured at the 
time of mammography screening. All cancer characteristics including cancer type (DCIS, 
invasive lobular, invasive other-including invasive ductal), stage (American Joint Committee 
on Cancer (AJCC) version 6 - 0, I, II, III, IV), estrogen /progesterone Receptor (ER/PR) 
status, HER2/neu, size, grade, nodal status, and laterality were identified using BCSC data. 
Comorbidity score in the year prior to the screening mammogram was derived from 
Medicare claims files using the Klabunde adaptation to the Charlson comorbidity score (28).
Statistical Analysis
Descriptive statistics were used to describe patient and cancer characteristics overall and by 
interval/screen-detected cancer diagnosis. We described the proportion of women receiving 
any additional breast imaging or biopsy and the type of primary surgical treatment in 
relation to receipt of preoperative MRI separately for interval and screen-detected cancers. 
Multivariable logistic regression models explored the relationship between interval cancer 
diagnosis, preoperative MRI use, and their interaction with type of primary surgical 
treatment.
To account for factors associated with interval cancers, we used models that adjusted for age 
at diagnosis (ages 66–69, 70–74, 75–79, and 80+), breast density (fatty/scattered or 
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heterogeneously dense/extremely dense), cancer type (DCIS, invasive lobular, invasive other 
– including invasive ductal), tumor size, AJCC stage, grade and nodal status. Odds ratios 
(OR) and 95% confidence intervals (95% CI) of mastectomy vs. breast conserving surgery 
are reported. Statistical significance was evaluated at the two-sided alpha = 0.05 level. 
Analyses were conducted using SAS (SAS 9.3 System Options: Reference, Second Edition. 
Cary, NC: SAS Institute Inc.; 2011.).
Results
Our sample included 204 women with an interval cancer diagnosis and 1254 women with a 
screen-detected cancer diagnosis. The median inter-quartile range (IQR) number of days 
from screening mammogram to diagnosis for interval cancers was 238 (129–306) and for 
screen-detected cancers was 23 (13–41). The median (IQR) number of days from diagnosis 
to primary surgical treatment for interval cancers was 20.5 (11–34.5) and for screen-detected 
cancer was 23 (11–38). In the study cohort, 205 (14%) had a preoperative MRI and 359 
(25%) had a mastectomy.
Patient and cancer characteristics were compared for the interval versus screen-detected 
groups (Tables I and II). Age was similar between the two groups. Compared to women with 
screen-detected cancers, women in the interval cancer group were more likely to receive 
preoperative MRI (21% interval vs. 13% screen-detected); have invasive cancer (25% 
interval vs. 14% screen-detected); have a higher cancer stage (II, III, IV) (48% interval vs. 
21% screen-detected); have larger tumors (≥20 mm, 47% interval vs. 21% screen-detected); 
a grade of poorly differentiated (33% interval vs. 25% screen-detected); and have one or 
more positive nodes (22% interval vs. 13% screen-detected).
In both the interval and screen-detected cancer groups, women receiving preoperative MRI 
were more likely to receive additional imaging with mammography or ultrasound than 
women without MRI (Table III). Among women with an interval cancer diagnosis, 30% of 
those receiving preoperative MRI had additional imaging with mammography or ultrasound 
compared to 22% of women without preoperative MRI. Women receiving MRI were also 
more likely to receive additional biopsies in both the interval and screen-detected sub-
groups.
Women with interval cancers were more likely to have mastectomies compared to women 
with screen-detected cancer (40% vs. 22%, respectively). However, among women 
diagnosed with interval cancer, the percentage of women with mastectomies was similar 
between those receiving and not receiving preoperative MRI (39.5% MRI vs. 40.3% No 
MRI). Among women with screen-detected cancers, mastectomy was slightly more common 
in women receiving MRI (26% MRI vs. 22% No MRI; Table III). In an adjusted logistic 
regression model for primary breast surgery, we found no interaction between interval 
cancer diagnosis and preoperative MRI (p=0.38). Receipt of preoperative MRI was not 
associated with odds of mastectomy (OR =0.99, 95% CI: 0.67–1.50) while interval cancer 
diagnosis was associated with significantly higher odds of mastectomy (OR=1.64, 95% CI: 
1.11–2.42).
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This study is the first to report the relationship between preoperative MRI and additional 
work-up and primary surgical treatment in sub-groups defined by breast cancer mode of 
detection (interval versus screen-detected). Previous studies have examined MRI use and 
outcomes in women with occult disease (29), however these studies have not reported 
findings for the clinically distinct interval cancer cases. Women with an interval cancer 
diagnosis were more likely to receive MRI. Although all women receiving MRI were more 
likely to receive additional imaging and biopsy, we found that a higher proportion of women 
with an interval cancer had a mastectomy than women with screen-detected cancers, 
regardless of MRI use (21% vs. 13%). Even after adjusting for patient and cancer 
characteristics, women with interval cancer were over 60%, more likely to have a 
mastectomy compared to women with a screen-detected cancer.
Many previous studies have accounted for cancer histology, stage, grade, tumor size and 
other prognostic cancer characteristics when assessing utilization of imaging, biopsy, and 
surgical management for breast cancer in relation to preoperative MRI. However, our results 
indicate that even after adjustment for these key prognostic factors, women with interval 
cancers were different from those with screen-detected cancers in relation to pre-operative 
MRI and surgical treatment. Women with an interval cancer were more likely to have a 
mastectomy regardless of whether or not they had a preoperative MRI, suggesting there may 
be other factors related to interval cancer that impact surgical management. For example, the 
anxiety level for a woman with an interval cancer may be higher than a woman with a 
screen-detected cancer because her cancer was missed on a previous mammogram. Hence, 
even though these women have more advanced disease and surgical options may be limited, 
women with interval cancer that do have surgical options may opt for a more extensive 
surgery to relieve her anxiety about risk of recurrence.
Interval breast cancers represent a challenging subgroup to study, given the relatively small 
numbers represented in existing population-based data. However, given the poorer prognosis 
among these women, this subpopulation is important to consider when evaluating the 
utilization and outcomes of breast imaging modalities such as MRI. Published literature on 
preoperative MRI has reported the conundrum of a preoperative modality that is optimal for 
detecting subclinical cancer foci and extent of disease yet with little evidence of benefits in 
short or long-term outcomes (1, 14). As the effectiveness of preoperative breast MRI is 
evaluated for benefits and harms, it is important to account for – and perhaps identify – 
subgroups of women for whom the influence of MRI may be diminished due to factors 
unique to those groups. This study begins to fill that gap for interval cancers.
This study has the strength of the BCSC data – a national, longitudinal sample with detailed 
clinical data – linked to Medicare claims. Although the BCSC-Medicare data are novel and 
rich, they limited our study cohort to women age 66 years and older. Therefore our findings 
may not be generalizable to younger women. Also, although we were able to explicitly 
identify interval cancers based on screening information and cancer registry data, we could 
not distinguish missed interval cancers (not identified by radiologist) from true interval 
cancers (not detectable on prior screening mammogram). This is a limitation seen in prior 
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studies (19, 30–32), and is less likely to influence the outcomes of this study, since we 
accounted for several factors that may relate to missed versus true interval cancers, such as 
lobular histology and breast density in adjusted analyses. We did not include neo-adjuvant 
therapy as a primary treatment; however, the median number of days to surgery (20.5 vs. 23 
days, respectively) was similar between the interval and screen-detected cancer groups, 
suggesting use of neo-adjuvant therapy was not more common in one group over the other.
There is no clinical consensus, and no recommendation for women with an interval cancer 
diagnosis to guide workup or treatment decisions (33). Our study suggests that women with 
interval cancers are more likely to receive MRI and mastectomy compared to screen-
detected cancers. There is little literature on patient and physician surgical treatment 
decisions following an interval breast cancer diagnosis. If women with interval cancer are 
more likely to receive mastectomy regardless of preoperative imaging, then the benefit of 
detecting additional cancer with MRI is not likely to matter. As the evidence base expands to 
inform patient choices for optimal outcomes, interval cancers patients are an important 
subgroup to evaluate, given the poorer prognosis for these women.
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Mammogram 87.37, 793.80, 793.82, V76.11, 
V76.12
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